Fewer Hospital Cases of Certain Brain Autoimmunity During COVID

Credibility

Interest

Key Takeaway

Hospital diagnoses of a certain type of autoimmune brain inflammation dropped during the COVID-19 pandemic, but cases were not more severe and age or sex did not change.

What They Found

Researchers looked at medical records from 24 German hospitals between 2017 and 2022 and counted patients with antibody-positive autoimmune encephalitis, a condition where the immune system attacks the brain. They saw fewer new cases during the pandemic years (2020–2022) than before (2017–2019). The drop was mainly in patients with antibodies that target proteins on the surface of nerve cells (think of antibodies sticking to the outside of a cell like tape on a wall), while the number of patients with antibodies to proteins inside cells stayed about the same. The severity of illness, patient ages, and whether patients were male or female did not change between the two time periods. Overall, the data do not support the idea that COVID-19 infection caused more antibody-positive autoimmune encephalitis or made it worse.

Who Should Care and Why

People with MS and their caregivers should notice this because autoimmune brain inflammation and MS can share symptoms like confusion, memory problems, or movement issues, so understanding trends helps doctors tell conditions apart. Neurologists and other healthcare providers benefit because the findings suggest COVID-19 did not increase this particular antibody-related brain problem, which may affect how doctors consider causes when new symptoms appear. Caregivers should know that fewer hospital diagnoses during the pandemic might reflect fewer people seeking care or changes in referral patterns, not necessarily a true drop in disease everywhere. For an MS patient, this means doctors are less likely to expect a rise in this antibody-driven brain inflammation because of COVID-19, but they will still check for it when symptoms match. In daily life, keep noticing and reporting new or changing symptoms to your care team; trends in populations don’t replace individual evaluation.

Important Considerations

This study looked at hospital records, so it may miss people who did not go to the hospital or were treated elsewhere during the pandemic; that matters because fewer diagnoses could reflect less testing, not fewer illnesses. The study only included antibody-positive cases confirmed in tests, so some autoimmune brain problems without detectable antibodies were not counted. Finally, the research is from specific centers in Germany and may not represent all countries or medical systems, so results might differ in other places.

Categories:

MS Progression Early Research MS Diagnostics

Whether you’ve recently been diagnosed with Multiple Sclerosis (MS) or are seeking to broaden your understanding of this complex, neurodegenerative disease, navigating the latest research can feel overwhelming. Studies published in respected medical journals like Neurology(R) neuroimmunology & neuroinflammation often range from early-stage, exploratory work to advanced clinical trials. These evidence-based findings help shape new disease-modifying therapies, guide symptom management techniques, and deepen our knowledge of MS progression.

However, not all research is created equal. Some clinical research studies may have smaller sample sizes, evolving methodologies, or limitations that warrant careful interpretation. For a more comprehensive, accurate understanding, we recommend reviewing the original source material—accessible via the More Details section above—and consulting with healthcare professionals who specialize in MS care.

By presenting a wide range of MS-focused studies—spanning cutting-edge treatments, emerging therapies, and established best practices—we aim to empower patients, caregivers, and clinicians to stay informed and make well-informed decisions when managing Multiple Sclerosis.

Back to News